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5SUMMARY
Since 1986, most Finnish children with terminal uremia or congenital nephrosis have been
treated with chronic ambulatory peritoneal dialysis (PD) prior to transplantation. This
study was designed to characterize and improve the management of pediatric patients on
PD, with special emphasis on children under 5 years of age.
The outcome in 34 children under 5 years of age on PD during 1986-1994 was
analyzed from patient files. A total of 30 patients were followed prospectively up to 12
months in 1995-1999. Clinical outcome was analyzed and compared with the results
obtained before 1995, and peritoneal equilibration tests and measurements of dialysis
adequacy were performed every 3 months. Utilization of tidal peritoneal dialysis (TPD)
was studied and compared with continuous cycling peritoneal dialysis (CCPD). Blood
pressure was measured with an automatic oscillometric device and with 24-h ambulatory
blood pressure monitoring. Cardiopulmonary status was evaluated and blood atrial
natriuretic peptide (ANP) levels were measured to find correlates with hypertension and
with high blood volume.
Length of hospitalization decreased during the study from 150 days to 95
days/patient-year in children under 5 years of age (60 days in all children). The peritonitis
rate decreased from 1 per 7.4 dialysis months to 1 per 9.4 months (difference not
significant) in children under 5 years of age. The need for antihypertensive medication
also decreased, and complications, such as seizures (26% of the patients in 1986-1994)
and pulmonary edema (41% of the patients in 1986-1994), did not appear during the
study period. Catch-up growth was seen in most of the patients treated between 1986-
1994, but was more evident during the prospective study period. Growth was significantly
better in the younger patients than in the older ones.  
No significant difference in peritoneal membrane transport was found between
children under and over 5 years of age. The mean weekly urea clearance (Kt/V) was
similar and stable in the two age groups (3.1 vs. 3.2 at baseline). At baseline, the mean
weekly creatinine clearance (CCr) was significantly lower in the younger patients (59 vs. 78
L/wk/1.73m2, p=0.004). During the study period, CCr increased in the younger children.
All patients reached the mean weekly urea Kt/V target of >2.0. The mean CCr target of >60
L/wk/1.73m2 was more difficult to reach, especially in the younger,  nephrectomized
patients. The target CCr was not reached by 79% and 29% of these children at baseline and
at 9 months, respectively.
In most children, TPD and CCPD provided adequate dialysis, but in patients with
high peritoneal membrane permeability TPD provided clearly better small-solute
clearances than CCPD. Thus, the ideal candidates for TPD are children with high
peritoneal permeability and ultrafiltration problems and children with mechanical outflow
6problems or outflow pain. TPD is, however, more expensive than CCPD, since more
dialysis fluid is needed.
High blood pressure was found in 52% and left ventricular hypertrophy (LVH) in
45% of the patients. Both were more common in the nephrectomized patients under 5
years of age. This may have been due to the difficulty in estimating the exact dry weight in
these patients. Blood ANP levels correlated significantly with the severity of hypertension
and LVH, especially in the nephrectomized patients. Thus, ANP was found to be a
valuable measure for facilitating the diagnosis of hypervolemia.
These studies show that PD outcome in children can be improved by knowing
peritoneal transport kinetics and by increasing dialysis adequacy in addition to good
clinical care. With such interventions, the dialysis outcome in children under 5 years of
age may be as good as in children over 5 years of age.
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8ABBREVIATIONS
ABPM ambulatory blood pressure monitoring
ANP atrial natriuretic peptide
ANP-C carboxy-terminal atrial natriuretic peptide
ANP-N amino-terminal atrial natriuretic peptide
AOD aortic diameter in end-diastole
BP blood pressure
BSA body surface area
BUN blood urea nitrogen
CAPD continuous ambulatory peritoneal dialysis
CCPD continuous cycling peritoneal dialysis
CCr creatinine clearance
CNF congenital nephrotic syndrome of the Finnish type
CNS congenital nephrotic syndrome
CRF chronic renal failure
dBP diastolic blood pressure
D/D0 glucose ratio of dialysate glucose at a given time to dialysate glucose at    
time 0
DOQI Dialysis Outcome Quality Initiative
D/P dialysate-to-plasma ratio
EDTA European Dialysis and Transplant Association
EF ejection fraction
ESI exit-site infection
ESRD end-stage renal disease
GFR glomerular filtration rate
H high peritoneal membrane permeability
HA high average peritoneal membrane permeability
HD hemodialysis
hSDS height standard deviation score
IPP intraperitoneal pressure
Kt/V urea clearance
L low peritoneal membrane permeability
LA low average peritoneal membrane permeability
LAS left atrial diameter in systole
LVEDD left ventricular end-diastolic diameter
LVESD left ventricular end-systolic diameter
LVH left ventricular hypertrophy
LVM left ventricular mass
LVPWD left ventricular posterior wall thickness at end-diastole
MTAC mass transfer area coefficient
NAPRTCS North American Pediatric Renal Transplant Cooperative Study
NIPD nightly intermittent peritoneal dialysis
NPHS1 nephrotic syndrome type 1
NPHS1 the nephrin gene
PD peritoneal dialysis
9Peak E wave peak velocity during rapid ventricular filling (early filling)
Peak A wave peak velocity at atrial contraction (late filling)
PET peritoneal equilibration test
PTH parathyroid hormone
RDA recommended dietary allowance
rhGH recombinant human growth hormone
rHuEPO recombinant human erythropoietin
sBP systolic blood pressure
Sept D interventricular septal diameter at end-diastole
TI tunnel infection
TPD tidal peritoneal dialysis
UF ultrafiltration
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INTRODUCTION
Chronic ambulatory peritoneal dialysis (CAPD) was adopted for use in pediatric patients
in 1978 (1). CAPD became popular in pediatric patients, because the continuous dialyzing
allows more freedom and provides steady control of blood volume and blood purification.
Even infants can be kept in acceptable clinical condition with CAPD while waiting for a
new kidney, which has allowed renal transplantation to become a standard therapy for end-
stage renal disease (ESRD) in childhood. Previously, all children with ESRD died. In
Finland, active medical treatment for uremia was started in 1967 for pediatric patients.
During the first 10 years, however, only a few small children were treated and most of the
older ones were treated in adult hemodialysis (HD) units. Some older children were
transplanted in adult units as early as in the 1960s. The first child was transplanted at the
Children’s Hospital, University of Helsinki, in 1971, after being treated with HD for a
longer period. CAPD treatment for Finnish pediatric patients was started in 1982, and for
infants in 1986. After 1987, CAPD was gradually replaced by continuous cycling
peritoneal dialysis (CCPD).
In Finland, there are more small children on renal replacement therapy than in most other
countries because of the high incidence (14.2 per 105 live births (2)) of the severe type of
congenital nephrotic syndrome type one (NPHS1), which is also called the congenital
nephrotic syndrome of the Finnish type (CNF) (3). In Europe as a whole, the annual
incidence of new ESRD patients per million children is 4.6, but in Finland 12.5 (4).
Since 1986, Finnish children with CNF have been treated actively. Today, optimal therapy
includes bilateral nephrectomy at the age of 6-10 months (5). Prior to renal
transplantation, these children are maintained on PD to improve their nutritional status and
to correct coagulation abnormalities (5). Because we have more small children on PD than
in other centers, and because small children have more complications during PD, it is
important for us to characterize the PD outcome in our patients and try to improve their
treatment.
Earlier studies on peritoneal membrane permeability in pediatric patients demonstrated
higher permeability in younger children (6-11). More recent studies have found similar
membrane permeability through the pediatric age range (12, 13). In infants and young
children on peritoneal dialysis (PD), determination of blood volume is difficult because of
growth. Measurements of weight and blood pressure (BP) and clinical investigations,
although important, are insufficient to estimate the exact dry weight of a growing child,
and approximately 50% of all children treated with PD are on antihypertensive drugs (14).
Maintenance of normal growth is difficult to achieve, and mortality and the number of
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infectious complications are higher in small children than in older children and adults (14-
17). New, more efficient PD regimens, such as tidal peritoneal dialysis (TPD), were
developed and studied in children aged 5-16 years (18-20), but their applicability to small
children was not known.
The present study was undertaken to evaluate the outcome in children treated with PD with
intensified clinical care and a controlled dialysis dose. Measurements of peritoneal
membrane permeability and dialysis adequacy were introduced and studied to enable
better control of the dialysis dose. In a prospective study, the results in children under 5
years of age were compared with those in children over 5 years of age. The outcome in
children under 5 years of age treated with CPD before 1995 was analyzed from patient
files and used as control material. TPD was studied in order to characterize its possible
benefits as compared with CCPD. Hypervolemia in the etiology of high blood pressure
was also studied, since it is a common and serious complication of PD in childhood.
12
REVIEW OF THE LITERATURE
END-STAGE RENAL DISEASE
More than half of the renal mass must be destroyed before the serum creatinine
concentration rises above normal or glomerular filtration rate (GFR) falls below 80% of
normal. Chronic renal insufficiency is present when the GFR decreases permanently to
less than 25% of normal and, at this stage, clinical abnormalities are often present.
Acidosis, growth failure, renal osteodystrophy, hypertension, and anemia are common, and
require medical treatment. But, despite medical treatment, prolonged anemia, acidosis, and
azotemia lead to the multisymptom complex known as uremia. When renal dysfunction
has progressed to the point at which dialysis or renal transplantation is required, the term
ESRD is used. According to the registry of the European Dialysis and Transplant
Association (EDTA), the incidence of ESRD in pediatric patients in Europe is about 500
patients annually, which is about 4.5 children per year per million children under 15 years
of age (4). Of these patients, 10% are less than 1 year of age, 15% are 2-5 years of age,
and 75% 6-14 years of age. According to the North American Pediatric Renal Transplant
Cooperative Study (NAPRTCS), 6% of ESRD patients are less than 1 year old, 17% 2-5
years of age, and 77% 6-17 years of age (21). However, in Finland there are 12.5 new
ESRD cases per million children, and 50% of them are less than 1 year of age (4).
The congenital nephrotic syndrome (CNS) is defined as proteinuria leading to nephrosis
soon after birth. NPHS1 includes all patients with a mutation in the nephrin gene
(NPHS1) (3), and CNF comprises all patients with the severe type of NPHS1, which is
unresponsive to medication lowering perfusion pressure. The main problem in CNF is
severe loss of protein, 90% of which is albumin (22), leading to severe hypoalbuminemia
with generalized edema. Patients with CNF are treated with albumin infusions (5).
Nevertheless, they develop muscular hypotonia, which hampers their motor development.
Because of urinary losses of gamma globulin and complement factors B and D, CNF
patients are especially prone to severe infections, despite the use of immunoglobulin
infusions and prophylactic antibiotics (23, 24). In order to prevent the loss of important
proteins, CNF patients are bilaterally nephrectomized and dialyzed at an early age. These
children differ from other ESRD patients, since they are not uremic before nephrectomy
and PD.                                                                                                                                           
The most common renal diseases leading to ESRD in Finland and in the rest of Europe
are listed in Table 1. In Europe, the most common renal diseases in children less than 2
years of age are congenital anomalies (4), but in Finland CNF predominates in patients
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under 5 years of age. However, in older children the diagnoses in Finland and in other
European countries are similar.
Table 1.  Distribution of primary renal diseases according to the registry of European
Dialysis and Transplant Association (EDTA, 1976-1989) and the Finnish Registry for
Kidney Diseases (FRKD, 1967-1997).
_______________________________________________________________
EDTA FRKD
<2 yrs 2-15 yrs <5 yrs 5-14 yrs
_______________________________________________________________
hypoplasia / dysplasia 24% 14%  8% 19%
cystic kidney disease 10%   7%  2%   9%
hereditary dis. (CNFa, CNSb)   4% 10% 84% (75%)c 19% (1%)c
pyelonephritis / anomal.d 15% 24% 17%
glomerulonephritis 14% 23%  3% 25%
hemolytic uremic syndrome 17%   1%
other 16% 22%  3%   9%
_______________________________________________________________
a congenital nephrotic syndrome of the Finnish type
b congenital nephrotic syndrome   
c percentage of all patients with CNF or CNS
d pyelonephritis, including urinary tract anomalies
MANAGEMENT OF UREMIA IN PEDIATRIC PATIENTS
Nutrition
Pediatric diets for uremic patients are generally liberal in order to achieve optimal growth
and to improve compliance. Restrictions are imposed only when there is a clear indication
of need. An energy intake of at least 100% of the recommended dietary allowance (RDA)
(25) for children of the same gender and height-age is recommended. High-calorie
formulas should be used, if needed, in order to meet energy requirements. Protein
requirements are high, especially in the youngest patients, because of losses of amino
acids and protein in the dialysate (26, 27).
Pharmacological treatment
Anemia is a common finding in PD patients. It is caused by decreased production of
erythropoietin (28, 29). To maintain adequate hemoglobin levels, blood transfusions were
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previously required by almost all patients, but are now rarely necessary because of the use
of recombinant human erythropoietin (rHuEPO) (30).
In chronic renal failure, renal production of 1,25-dihydroxyvitamin D3 (calcitriol) and
renal phosphorus excretion decrease. Renal and intestinal calcium reabsorption decreases
because of decreased circulating 1,25-dihydroxyvitamin D3, resulting in low serum ionized
calcium. Reduced ionized calcium concentration stimulates secretion of parathyroid
hormone (PTH) by the parathyroid glands (31), which in turn increases osteoclastic
activity and the release of calcium from bone. High serum phosphorus also exerts a direct
stimulatory effect on PTH secretion, with the result that renal excretion of phosphorus
increases (32). Without vitamin D3 substitution and phosphate restriction, these complex
interactions lead to secondary hyperparathyroidism and bone destruction (33-35).
Today calcium carbonate is used for hypocalcemia, and as a phosphate binder. Sodium
polystyrene sulfonate resin is used for hyperkalemia. Water-soluble vitamins should be
added, and fat-soluble vitamins, except vitamin D, should in general be avoided (36).
Antihypertensive drugs are given if needed.
Dialysis treatment
Hemodialysis
Hemodialysis uses extracorporeal perfusion to transfer low-molecular-weight solutes into
and out of the body, and to remove water by ultrafiltration. It has been used to treat
children with acute and chronic renal failure for over 25 years. HD is used more
commonly in older children than younger ones. In 1996, 37% of all pediatric ESRD
patients, compared with 12% of patients under 5 years of age, were treated with HD in
North America (37). The proposed advantages of chronic HD include the successful long-
term use of treatment, minimal technical assistance required by the patient and parents, and
relatively low hospitalization rates with 11- 26 hospital days per patient-year at risk (38,
39). In contrast to the arteriovenous fistulas used in adult patients, the most common type
of vascular access in children is a dual-lumen venous catheter, usually in the subclavian or
jugular vein (14). The most frequent cause of morbidity in HD patients is the need for
access revision, caused by infection, clotting, or malfunction (37). Catheterization should
therefore be replaced as quickly as possible by fistulas or grafts, which are not without
complications in small children, on account of the small caliber of their blood vessels (40).
In general, however, there is no difference in the longterm outcome of HD and PD (41).
Although PD is today the preferred treatment form for infants and small children, HD
treatment has been developed to become more suitable for small children also. Overall
15
survival rates as high as 52% have been reported for infants weighing less than 5 kg (42).
Thus, in experienced hands, HD can also be successfully used for infants with ESRD.
Peritoneal dialysis
PD takes place across the peritoneal membrane between the blood in the capillaries of the
peritoneum and the infused dialysis solution. The peritoneal membrane is a
semipermeable membrane which allows small molecules and water to pass through faster
than larger molecules. PD is an important renal replacement therapy for pediatric patients
because of its safety and simplicity. The first child was treated with CAPD in Canada in
1978 (1). CAPD was originally designed for adult patients, and lack of equipment and
other supplies suitable for use in children hindered its spread in pediatric patients.
However, the time interval between the adoption of CAPD in North America and in
Europe was short, and the breakthrough of PD in pediatric ESRD patients began in the
80s (43). The introduction of CCPD, the first automated PD modality, in the early 80s
(44, 45) was an important milestone in increasing the use of PD. CCPD was originally
developed to reduce the frequency of peritonitis and the complications caused by high
intra-abdominal pressure (44, 45). The first experiences with CCPD in pediatric patients
were encouraging (45, 46), and it gradually became the most popular PD modality,
although daily CCPD clearances of small and middle-sized molecules were not better than
those given by CAPD with the same quantity of dialysate (45). TPD was introduced in
1990 to increase the efficacy of dialysis without sacrificing the advantages of CCPD and
CAPD (47). Preliminary results in schoolchildren showed that TPD was able to provide a
dialysis outcome equal to that of CCPD within a shorter time (18, 19). In recent studies,
however, TPD has been shown to be superior only when high dialysis flow is used in
patients with high average / high peritoneal membrane permeability (20, 48, 49). For most
infants with ESRD, the first treatment modality has become automated PD, and for
example in Italy, during 1986-1993, no infants were treated with CAPD or chronic HD
(50).      
The most common PD techniques are illustrated in Figure 1. CAPD treatment is given
continuously. Three exchanges are performed manually during the day and one before
bedtime. The overnight exchange time is usually 8-10 hours. The dialysate volumes for
day and night exchanges are usually the same (about 1000 ml/m2). CCPD treatment is
also given continuously. Usually 5-6 exchanges are made with the help of a cycler
machine during the night, combined with a long daytime exchange. It is also possible to
perform extra daytime exchanges manually. The nightly dialysis time is 8-12 hours, the
night exchange volume usually being 1000-1200 ml/m2, but the day exchange volumes are
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smaller (about 500 ml/m2). The nightly intermittent peritoneal dialysis (NIPD) is provided
with the help of a cycler machine every night, lasting for 8-12 hours. The daytime is free
of treatment. There are usually more cycles performed during the night with NIPD than
with CCPD. The exchange volume is about 1000-1200 ml/m2. In TPD, a constant volume
of dialysis solution (reserve volume) is maintained in the peritoneal cavity throughout the
treatment session. Over and above this reserve volume, rapid fixed tidal volume exchanges
are carried out with the help of a cycler machine. The nightly dialysis time is usually 8-10
hours. The initial fill in children is about 1000-1200 ml/m2, and the tidal volume
exchanges are usually made with a volume which is 50% of the initial fill. Day exchanges
are optional. With all treatment modalities, the glucose concentration is chosen according
to the patient’s ultrafiltration (UF) needs.
ml/m2       day night
       1000
CAPD
            0
       1000
CCPD                      500
            0
       1000
NIPD
            0
       1000
TPD
         500
            0
Figure 1.  The most common regimens of peritoneal dialysis. The vertical line represents
the change from day to night, and the horizontal lines the dialysate volume of 0 ml/m2.
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PERITONEAL TRANSPORT KINETICS
Peritoneal equilibration test
The peritoneal equilibration test (PET) was developed to investigate peritoneal membrane
function (51), so as to be able to individualize and optimize the patient’s PD regimen. PET
is based on ratios of dialysate-to-plasma solute concentrations (D/P) to define the rate of
solute transport across the peritoneal membrane. Similarly, the ratio of glucose in the
dialysate at a given time to the initial glucose concentration immediately after instillation of
dialysate into the peritoneal cavity (D/D0 glucose) is used to predict the likelihood of
achieving ultrafiltration. The D/P and D/D0 glucose ratios of an individual patient are
plotted against standard curves, thereby permitting categorization of the patient’s
membrane transport as rapid (high; H), slow (low; L) or average (high average; HA, low
average; LA) (Figure 2). PET should be performed at earliest 4 weeks after an acute
episode of peritonitis. At least 4 weeks are required, because peritonitis induces a
hyperpermeable state in the peritoneum, which normalizes within 2 to 4 weeks (52).
PET has been used in pediatric patients, but its application has been controversial and
problematic, since the test was initially introduced for use in adult patients. Early studies
have demonstrated a trend toward higher membrane permeability in young children as
compared to older children and adults (6-11). However, in these studies the test volume
was related to body weight instead of body surface area (BSA), which has been later
recommended for calculation of the test volume (53), since BSA is proportional to the
surface area of the peritoneal membrane (54). Despite calculating the test volume
according to BSA (1000-1100 ml/m2), reports about peritoneal membrane transport were
inconsistent  (13, 55, 56). In 1996, the most comprehensive report with 95 patients was
published (12). In this multicenter study, peritoneal membrane transport was found to be
similar across the pediatric age range, and pediatric reference curves were defined (12).
Very few studies have measured alterations in the peritoneal equilibration rate over time in
pediatric patients and the short follow-up times in children have hindered interpretation of
the results. Peritonitis has been assumed to be a risk factor for deterioration of peritoneal
membrane function in children (57). Latterly, however, peritoneal membrane permeability
has been shown to be relatively stabile in patients with no history of peritonitis and to
increase in patients who have experienced one ore more peritonitis episodes (58, 59).
Increased microvascularization of the peritoneal membrane, in response to infections and
chronic exposure to a high glucose concentration, has been suggested to explain the
increased membrane permeability (59). Peritonitis, especially that caused by
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Pseudomonas and alpha streptococcal organisms, may increase the risk of peritoneal
membrane failure (60, 61).
Figure 2.  PET reference curve for creatinine. Lines represent mean ± 1SD. High, high
average, low average, and low represent the peritoneal membrane transport categories.
Mass transfer area coefficient
In the absence of an osmotic gradient between the blood and the dialysate, the rate of
solute movement is directly proportional to the solute concentration gradient, the
membrane size, and the diffusive permeability of the membrane for the solute. For small
solutes, the concentration gradient decreases exponentially and for larger solutes almost
linearly. The surface area and the diffusive permeability are combined into a single
parameter, the mass transfer area coefficient (MTAC). MTAC represents the maximal
clearance of the membrane for a solute at the point when the dialysate concentration of the
solute is zero. MTAC has been assumed to be constant in a specific patient from exchange
to exchange (62).
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DIALYSIS ADEQUACY
Since the introduction of dialysis treatment, efforts have been made to define the
appropriate dose for purification. Urea and creatinine clearances have been used as
markers of small solute clearance. Kt/V represents the urea clearance normalized for the
volume of urea distribution. Kt means the urea clearance during the sampling period and
V is the urea distribution volume, which is considered equivalent to total body water. CCr
represents the creatinine clearance, which is measured similarly to Kt/V over 24 hours, but
is expressed as liters of clearance per week. Dialysis adequacy has been used to describe
the minimally acceptable dose of dialysis, below which a significant increase in morbidity
and mortality would occur. In adult patients, mortality is often used as a criterion for
dialysis adequacy (63), but it is more difficult to define adequate dialysis in children,
because of the small number of dialyzed children, the short duration of dialysis, and the
difficulty of normalizing the measured dialysis doses across the range of body sizes. The
Dialysis Outcome Quality Initiative (DOQI) guidelines published in 1997 were based on
a review of 260 published articles (63). For adult patients, the CAPD doses delivered
should be a total of weekly urea Kt/V >2.0  and a total of weekly CCr >60 L/1.73 m2.
According to mathematical calculations, the equivalent delivered doses for CCPD and
NIPD should be 2.1 and 2.2 for urea Kt/V, and 63 and 66 L/wk/1.73m2 for CCr. Since no
data linking PD dose with clinical outcome were available for children, the use of the adult
recommendations as the lower limit of PD adequacy was proposed for children (63).
CLINICAL OUTCOME OF PEDIATRIC PD
Hospitalization
Hospitalization is an important aspect of morbidity in pediatric PD patients. Pediatric PD
patients spend 13-100% more days in hospital than HD patients (38, 39). Hospitalization
rates of 15-30 days per year at risk have been reported in children (17, 39), but the
numbers of hospital admissions and hospital days have been shown to be much higher in
younger children than in older children (38). Peritonitis is the most frequent cause of
hospitalization in pediatric PD patients (33% of admissions), followed by catheter-related
problems (19% of admissions) (64).
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Dialysis access
The median survival time for PD catheters has been reported to be 1-3 years (37, 65).
According to 1996 NAPRTCS data, about 20% of catheters need to be replaced, mostly
because of catheter malfunction (47%), peritonitis (18%), or exit-site/tunnel infection
(17%) (37). The most common combination of PD access in pediatric patients is a
Tenckhoff curled catheter with a single cuff, a straight tunnel and a lateral exit-site (37,
66).
Dialysis adequacy
Published information on dialysis doses delivered in children is limited. However, initial
studies in pediatric patients have shown that CCr targets of >60 L/wk/1.73m2 are difficult to
achieve (67, 68); in fact, only Walk et al. have succeeded in showing, in 19 patients
(median age 9 years), a mean CCr of 74±47 L/wk/1.73 m2, achieved with CAPD and NIPD
therapies (69). In contrast, the target weekly urea Kt/V clearances are achieved in most
pediatric patients (67-70). There are only a few studies correlating clinical outcome and
dialysis adequacy in pediatric patients. In 1997, Walk at el. reported urea Kt/V and CCr to
correlate weakly with serum albumin and protein intake (69), but Schaefer et al. could not
confirm this (68). In 1999, however, Schaefer et al. reported that the peritoneal transporter
state was an independent determinant of growth, and suggested that high transporters were
at risk of poor growth and of becoming obese (68).
Growth
Malnutrition, acidosis, anemia, and renal osteodystrophy are believed to impair growth in
children on RRT (71-73). Because one third of a child’s growth occurs during the first 2
years of life, infants are at greatest risk of loosing growth potential (74, 75). Thus, growth
retardation in children whose disease begins after infancy usually is less than that seen in
children with congenital disease (76). In some children with chronic renal failure (CRF),
optimal nutrition and medical care have been shown to provide normal growth velocity (77,
78). However, significant catch-up growth to correct the height lost has not been obtained
without recombinant human growth hormone (rhGH) during conservative therapy (77,
78). At transplantation, according to the NAPRTCS registry, the mean height deficit for
pediatric patients was –2.16 SDS (14). Younger recipients had a greater height deficit at
the time of transplantation (14). Early studies showed better growth in children treated
with PD than with HD (79, 80), but recently growth has been shown to be comparable
under PD and HD (81), and even catch-up growth has been reported in children treated
21
with HD (82). However, optimization of nutritional support and medicinal therapy with
vitamin D, rHuEPO, and mineral supplements has not uniformly improved growth during
PD treatment (17, 37, 83-85). Caloric supplementation far beyond 100% of RDA (25) has
been suggested to lead to obesity rather than to improved growth (86, 87). However, some
recent studies have suggested that a high energy intake correlates with better growth (84,
88, 89). Catch-up growth has been achieved in pediatric PD patients mostly only with
rhGH therapy, which is recommended during PD to prevent further loss of height (17,
90).
Complications
Peritonitis
Peritonitis is the major cause of morbidity and technique failure in PD patients. The
incidence of peritonitis is higher in children than in adults (15, 91-93), and within the
pediatric population, infants and children up to 5-6 years of age develop peritonitis more
frequently than older children (37, 65, 66, 94). Reported incidences of peritonitis range
from one episode per 8 to one per 29 treatment months (14, 17, 64, 65, 95, 96), but recent
data from the NAPRTCS registry, involving more than 2000 patients, gives an overall
incidence of one episode for every 13 patient-months (37). The peritonitis rate for infants
under 1 year of age was one per 9.9 months, for children 2-5 years of age one per 12.7
months, and for children over 6 years of age one per 14.3 months (37). The exact etiology
of the higher peritonitis rate in infants is unclear, but potential predisposing factors might
be hypogammaglobulinemia (97), upper respiratory tract infections (61), and a shorter
subcutaneous tunnel with its exit-site near the diaper area.
The recommended definition of peritonitis during PD is a dialysate white blood cell count
of at least 100/µl, of which over 50% should be polymorphonuclear leukocytes (92).
Other signs include abdominal pain, and/or cloudy peritoneal fluid, fever, and identified
organisms in culture and/or Gram stain (92). The predominant pathogens are Gram-
positive organisms (50-60%), followed by Gram-negative organisms (10-30%) and fungi
(<5%) (14, 64). The commonest Gram-positive organism is Staphylococcus aureus
followed by Staphylococcus epidermidis, and the commonest Gram-negative organisms
are Enterobacter and Pseudomonas (64, 98). The recommended initial treatment for
peritonitis includes vancomycin and ceftazidime or aminoglycoside intraperitoneally (99),
adjusted later according to the microbial findings. In the 1993 guidelines, intermittent
intraperitoneal therapy with vancomycin (once a week) and aminoglycosides (once daily)
were included in the recommendations, but only for adult patients (99). In the most recent
updated guidelines in 1996, limited usage of vancomycin and return to first-generation
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cephalosporins instead of vancomycin was recommended, because of the increasing
prevalence of vancomycin-resistant microorganisms (92). In a recent study, however,
vancomycin, administered intermittently to pediatric patients in two doses 7 days apart,
was found to be as effective as when administered continuously (100).
Exit-site infections and tunnel infections
The most common definition of exit-site infection (ESI) is redness and/or skin induration,
and purulent discharge at the catheter sinus, and for tunnel infection (TI) purulent outflow
from the tunnel, and redness and induration above the tunnel. The most common
organisms causing ESI in pediatric PD patients are Staphylococcus aureus (46%),
Staphylococcus epidermidis (26%), and Pseudomonas aeruginosa (10%) (101). Because
of lack of standardized criteria for the diagnosis of ESI and TI, studies reporting their
incidences in pediatric patients are sparse. Levy et al. reported an incidence of ESI of one
episode per 6 months (101), and, according to NAPRTCS data, 28% of patients have had
ESI at 12 months of PD (37). Microbial analysis of the causative agent is mandatory in
the diagnosis of ESI and TI. Gram-positive bacteria should be treated with penicillinase-
resistant penicillin or with first-generation cephalosporins orally for 7-10 days (92). For
Gram-negative organisms, ceftazidime is recommended (92). Catheter removal is indicated
in case of chronic ESI or TI, and if ESI or TI is associated with Gram-negative peritonitis,
especially when due to Pseudomonas, or with Staphylococcus aureus peritonitis or fungal
peritonitis (102).
Hypertension
About 50% of all children on PD are receiving antihypertensive drugs (14). BP studies in
pediatric PD patients are sparse. Lingens et al. reported hypertension in 47% of their
pediatric PD patients aged over 6 years and, when measured with an ambulatory BP
monitor (ABPM), 70% were found to be hypertensive (103). ABPM has also been used
in pediatric patients to measure the BP profile. Patients with renal diseases have been
shown to have altered BP profiles with increased nocturnal BP as compared with healthy
children (103, 104).
Estimation of the exact dry weight of infants and young children on PD is difficult.
Weight gain may be interpreted as growth, although it may have been caused by retention
of sodium and water. A normal blood volume is, in general, reached in ESRD patients with
residual renal function through both dialysis and residual renal function. In contrast, in
nephrectomized children, blood volume is regulated only by dialysis. Therefore it is
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difficult to avoid hyper- or hypovolemia. However, normal volemia is aimed at limiting the
use of antihypertensive medication. 
Vasoactive hormones such as atrial natriuretic peptide (ANP), cyclic guanosine
monophosphate, and plasma catecholamines have been studied with the aim of correlating
them with blood volume (105, 106). ANP is a cardiac hormone that is secreted primarily
by atrial myocytes in response to local wall stretch. ANP reduces systemic BP and
intravascular volume through relaxation of vascular smooth muscle, through increasing
salt and water excretion, and through facilitating trassudation of plasma water to the
interstitium (107). Pro-ANP 1-126 is cleaved by a membrane protease to release a
vasoactive carboxy-terminal peptide (ANP-C) and amino-terminal ANP (ANP-N) (108).
The plasma level of ANP-C in healthy children more than 4 weeks of age has been shown
to be similar to that of healthy adults (109). Plasma levels of ANP-C are known to
increase in renal failure (110, 111), in association with hypervolemia in adult patients on
HD and PD (105) and in pediatric patients on HD (111, 112), as well as in association
with cardiac dysfunction in adult PD patients (106). However, there are not many studies
dealing with ANP in pediatric PD patients. In one pediatric study, the plasma level of
ANP-C was found to be increased in PD patients with fluid overload, but not in those with
an apparently normal blood volume (113). ANP-N has been found to be more stable ex
vivo than ANP-C, which makes its use in clinical work easier and more reliable (114, 115).
Since 1993, a few clinical studies dealing with ANP-N have been published, showing a
significant correlation with the decrement in relative blood volume in adult patients on HD
(116), and an even better correlation with LVH and LV dysfunction than with ANP-C
(117-119). Recently, similar results have been shown in pediatric patients with heart
disease (120).
Cardiac complications
Chronic volume overload, systemic hypertension, and anemia predispose to left ventricular
hypertrophy (LVH) and diastolic dysfunction (121). According to echocardiographic
studies, increased left ventricular mass (LVM) and impaired left ventricular diastolic
function are common in both adult and pediatric PD patients (122-125).  In a few studies,
however, the cardiac state has been shown to improve as a result of better control of
volemia, blood purification, BP, and anemia during PD (126, 127).
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Other complications
Inguinal and abdominal wall hernias are common in children treated with PD and 23 -
40% of the patients have been reported to develop hernias (128, 129). Young males are at
greatest risk for inguinal hernias. A dialysate volume of more than 1200 ml/m2 (over 800
ml/m2 in neonates) has been shown to increase the intraperitoneal pressure (IPP) in
children from 8 to 12 cm of water, but substantial intra-individual variations for IPP were
found after the same amount of fluid (130). The effect of high IPP on the development of
hernias was demonstrated in a recent study (131). Hydrothorax is an uncommon
complication of PD, which is found more often in small children (132, 133). The leak has
been suggested to be the result of raised intraperitoneal pressure due to small defects in
the pleuroperitoneum covering the diaphragm (134).
Mortality
The overall mortality rate for the pediatric PD population is 9-11% (37, 65). Mortality
rates for children less than 6 years of age are reported to be greater than for older children
(37, 50, 65). According to the NAPRTCS database, the mortality rate for children less than
2 years of age was 22.5% and for children 2-5 years of age 11.5%, as compared with 5-
7% for children 6-17 years of age (37), the most common causes of death being
cardiopulmonary disease and infection (66).
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AIMS OF THE STUDY
Because of the relative abundance of young children on PD in Finland, the PD outcome
was studied for children under and over 5 years of age. The main objective of the present
study was to investigate whether the PD outcome in small children differs from that in
older children and whether the outcome could be improved through intensified clinical
care and PD adequacy control. The specific aims of the study were:
1. to retrospectively analyze the clinical PD outcome in children under 5 years of age (I),
2. to evaluate peritoneal transport kinetics and its changes over time, and any differences
between children under and over 5 years of age (II),
3. to study the clinical PD outcome under PD adequacy control, and to compare the
outcomes of the age groups under and over 5 years of age with one another and with
previous results (III),
4. to compare PD adequacy and outcome of CCPD and TPD therapies (IV), and
5. to specify the impact of hypervolemia in the etiology of hypertension (V).
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PATIENTS AND METHODS
ETHICAL CONSIDERATIONS
The study design was approved by the Ethical Committee of the Hospital for Children and
Adolescents, University of Helsinki. Informed consent was obtained from the patients
and/or their parents or guardians after the design and purpose of the study had been
explained.
PATIENTS
The diseases of the patients included in studies I-V are listed in Table 2.
Table 2.  Demographic data of patients included in studies I-V.
______________________________________________________________________
I II III IV V
Patient number 34 28 21 17 21
Renal disease
CNF (NPHS1 mutation) 27 10 10 9 11
CNS 3 - - - -
obstructive uropathy 1 3 3 3 2
cystic kidney disease 1 3 2 - 3
reflux nephropathy - 1 1 1 1
RPGNa - 1 1 1 1
prune-belly syndrome - 2 1 1 2
Alport syndrome - 1 1 1 -
Wegener’s granulomatosis - 2 1 - -
Denys-Drash syndrome - 1 1 1 1
otherb 2 4 - - -
Age at baseline, years 1.6±1.0 7.8±5.5 5.5±5.0 5.1±5.0 5.3±5.3
(range) (0.6-4.3) (0.3-16.6) (0.3-14.4) (0.3-14.4)  (0.2-14.8)
<5 years 1.6±1.0 1.7±1.3 1.0±0.6 1.0±0.7 0.9±3.4
  ≥5 years - 11.2±3.8 9.6±3.4 9.7±3.3 10.2±3.4
Nephrectomy (<5/≥5yr) 29 (29/-) 12 (8/4) 12 (9/3) 10 (8/2) 13 (10/3)
______________________________________________________________________
a  
 rapidly progressive glomerulonephritis
b
  neuroblastoma, dysplasia renis, IgA nephropathy, lupus erythematoides disseminatus
   (LED), dysplasia fibromuscularis arterialis, and optic nerve coloboma with renal disease.
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Study I:  The study included all children under 5 years of age who had been placed on
chronic peritoneal dialysis at the Hospital for Children and Adolescents, University of
Helsinki before 1995. The patient records were analyzed from initiation of dialysis to
renal transplantation (0.8±0.4 years).
All pediatric patients treated at the Hospital for Children and Adolescents with
maintenance peritoneal dialysis were potential candidates for the prospective studies (II-
V). Between 1995 and 1998, all patients being maintained on or starting peritoneal dialysis
were asked to participate in the study, with the aim of obtaining equal numbers of patients
for the groups under and over 5 years of age. A total of 30 patients were included; 15 were
under 5 years of age. Two patients aged over 5 years were followed twice: one patient was
without PD for 1 year, and the other for 4 months, after their first kidney transplantation.
In seven patients (three patients were under 5 years of age) the follow-up time was less
than 3 months because of early renal transplantation. Twelve patients were studied during
the entire follow-up period of 12 months, six of whom were under 5 years of age. The
remaining 11 patients were followed for 3–9 months. The mean dialysis time prior to
examination was 0.38±0.49 years (0.02-1.86 years), and the mean follow-up time in the
study was 0.70±0.37 years (0.06-1.08 years).
Study II:  The PET results for 24 patients were analyzed. In addition the results for four
other patients were available. In the latter patients, only the regular PETs and adequacy
measurements were performed. Baseline PETs were analyzed for all patients, and control
PETs for 21 patients after 0.8±0.4 years. The latest available PET served as a control for
the study of long-term changes in peritoneal membrane function. In some patients, PETs
were performed every 3 months even after the 12-month study period. Accordingly, in
these patients the latest available PET was performed after 12 months. The mean dialysis
time before the study was 0.39±0.42 years. At the start, the mean age of the 10 children
under 5 years of age was 1.7±1.3 years and of the 18 children over 5 years of age
11.2±3.8 years.
Study III:  All the patients followed for at least 3 months were included in the study. For
the analysis of clinical outcome under adequacy control, the final number of patients was
21. The patients were divided into two groups according to age; under 5 years of age
(n=10, 1.0±0.6 years) and over 5 years of age (n=11, 9.6±3.4 years). The mean follow-up
period was 0.8±0.2 years.
Study IV:  Seventeen patients were enrolled in the study comparing the efficacies of
CCPD and TPD therapies. However, four patients tested only with one modality were
excluded from further analysis. The remaining 13 patients were dialyzed for at least 6
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months with one modality and for 3-6 months with the other, to allow comparison. The
patients were seen every 3 months. Thus, if the patient was followed for 6 months on the
first modality and for less than 6 months on the second, the mean of the two
measurements obtained during the first modality was compared with the single
measurement during the second modality. At the start of the study, nine patients were
under 5 years of age (1.0±0.7 years).
Study V:  Twenty-one patients were enrolled in the study of hypertension. Baseline data
were available for all these patients, and control data for nine patients (after 0.9±0.2
years). Eleven patients were under 5 years of age (0.9±3.4 years).
METHODS
A retrospective analysis was made from data collected from the patients’ files (I). The
following data were collected: characteristics of PD, medication, laboratory data, peritonitis
data, and measurements of height and weight. In the prospective studies the observation
period was up to 12 months unless renal transplantation was performed earlier. All
patients were seen every 3 months for clinical and dietary examination, laboratory tests,
BP measurements, dialysate collection, and PETs. Between these visits, the patients visited
their local hospitals every 2-4 weeks.
Peritoneal dialysis (II-V)
The dialysate volume was calculated according to the patient’s BSA; a nightly exchange
volume of 1000 ml/m2 of BSA, and a last fill of 500 ml/m2 were targeted in all the
prospective studies. All patients received nightly automated peritoneal dialysis and a long
daytime exchange. In the anephric children, two additional exchanges were performed in
the late afternoon to avoid hypertension. The target volume of the additional daytime
exchange was 500 ml/m2 of BSA per exchange. The glucose concentration used varied
according to the estimated dry weight of the patient at every check-up. None of the
children in the prospective studies were treated with CAPD. CCPD therapy consisted of
approximately 9 (8-14) exchanges throughout the night. The initial TPD prescription
consisted of a fill volume of 1000 ml/m2 and 21-24 tidal exchanges with 50% of the initial
fill, leading to a nightly dialysate flow rate of approximately 50 ml/kg/h. Curled, single
cuff Tenckhoff catheters (Quinton Instruments, Seattle, WA, U.S.A.) were used. In most
patients, the tunnel was straight and lateral and the exit-site pointed upward. The cycler
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machines used were PAC X, PAC Xtra, Home Choice (Baxter Healthcare, Illinois,
U.S.A.), PD 100 (Gambro, Lund, Sweden), and PD-Night (Fresenius AG, Schweinfurt,
Germany).
Collection of dialysate and urine  (III, IV)
A complete 24-h collection of dialysate and urine was obtained from each patient every 3
months. This was modified to make it possible to keep the patients in hospital only 2
days. A modified 24-hour dialysate collection was started at noon on day 1 with
replacement of the last fill volume after a complete dwell; if there were day exchanges, they
were performed as usual. Night dialysis was performed 2-4 hours earlier than for the
patient’s normal dialysis program. After the night dialysis, an 8-hour dwell was performed
with 1000 ml/m2 of 2.27% glucose dialysate.
Peritoneal equilibration test and mass transfer area coefficient  (II-IV)
Immediately after dialysate collection, a 4-hour PET was performed with 1000 ml/m2 of
2.27% glucose dialysate. Blood samples were taken immediately after completing the
dialysate collection, and again after 2 hours (during PET). Dialysate samples were taken
immediately after completion of the infusion, and after 1, 2, and 4 hours. To achieve a
physiologically consistent relationship between the blood and dialysate concentrations of
the particular solute, all serum values, except albumin, were expressed as concentrations
per unit volume of plasma water. This was achieved by dividing the serum values, except
that of albumin, by a factor 0.93, thereby correcting the plasma volume for protein and
lipid contents (135). Dialysate and serum creatinine assays were further corrected for
glucose interference, as suggested by Twardowski et al. (51), using a correction factor of
0.51 specific to our laboratory. Peritoneal transport was estimated from the dialysate-to
plasma ratios at 0, 1, 2, and 4 hours, and glucose transport from dialysate to patient was
estimated from dialysate glucose at a given time to dialysate glucose at time 0. In study IV,
pediatric reference values of 4-h D/P for creatinine (12) were used to determine the type of
peritoneal membrane transport.
Calculation of the MTAC, characterizing the diffusive permeability of the peritoneal
membrane, was based on the two-pool Pyle-Popovich model (136), and was further
expressed as a weighted average (II).
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Dialysate collection and kinetic studies were performed at least 1 month after completing
antibiotic therapy for peritonitis. The 1.4 version of the PD ADEQUEST program (Baxter
Healthcare, Deerfield, IL, U.S.A.) was utilized to calculate the MTAC values (II), and total
weekly CCr and urea Kt/V from the modified 24-hour collection (III, IV). For the clearance
calculations, total body water was estimated from height and body weight, using the child-
specific equation of Friis-Hansen (137). BSA was calculated, using the child-specific
equation of Haycock et al. (138). In 1995, we used a urea Kt/V of >1.7 and a CCr of >40
L/wk/1.73m2 as target clearances (139). In 1997, we adopted new raised targets: a urea
Kt/V of >2.0 and a CCr of >60 L/wk/1.73m2 (140) (III, IV). The PD ADEQUEST
program was further used to obtain mathematical simulation of the results of the patient’s
usual 24-hour dialysis regimen, and of changes planned in the PD prescription.
Diagnosis and treatment of peritonitis (II, III)
As criteria of peritonitis, we used cloudy peritoneal fluid and an elevated dialysate white
cell count >100/µl with >50% polymorphonuclear cells. Facultative findings were
abdominal pain and/or fever. Peritonitis therapy outside our institution consisted of
loading doses of vancomycin (15 mg/kg) and netilmycin (1.8 mg/kg) intraperitoneally for
2 hours, followed by 8 to 12 daily exchanges of dialysate containing 30 mg/L vancomycin
and 8 mg/L netilmycin. Patients treated at our institution received intermittent
intraperitoneal antibiotic treatment: vancomycin in a dose of 30 mg/kg in one 6-hour
exchange, and netilmycin 20 mg/L using one dose daily. The serum vancomycin
concentration was followed, and the dose was repeated after one week or earlier if the
serum concentration fell below 5 µg/ml. Antibiotics were later adjusted according to the
microbial findings and continued until the peritoneal fluid leukocyte count and C-reactive
protein had normalized after 8 to 10 days. Heparin (500 U/l) was added to the dialysate
until the effluent was clear.
Nutrition and dietary examination (III)
Nasogastric tube feeding was used if spontaneous protein and energy intakes were clearly
below our target for chronological age. Tube-feeding was based on infant milk and cereal
formulas, supplemented with a casein-based protein product and glucose polymers. Rape
seed oil and glucose polymer were added to the diet if additional energy was needed. The
protein allowance was restricted only if blood urea nitrogen (BUN) rose above 40
mmol/L. Additional changes in diet were made if the serum phosphorus concentration
rose above the reference values. Adherence to diet was checked using a 3-day food record.
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Nutritional intakes were analyzed using a computer program (Unidap SFO4a, van den
Berg Foods).
Medication (II-IV)
Water-soluble vitamins were added to the diet and vitamin D was given as oral
alphacalcidol pulse therapy two to three times weekly (141). The alphacalcidol dose was
adjusted to keep the serum intact PTH concentration between 80 and 150 ng/L. Calcium
carbonate was used as a calcium supplement and phosphate binder. Sodium polystyrene
sulfonate resin was given, if needed, for hyperkalemia. All patients received rHuEPO
subcutaneously; the starting dose was 50 U/kg three times weekly. The dose was later
adjusted to keep the blood hemoglobin concentration at about 110 g/L. During rHuEPO
therapy, the patients received oral iron (Fe++) supplementation, with a starting dose of 5
mg/kg per day. One patient was given recombinant human growth hormone (III).
Auxological measurements (I, III)
Height and weight were measured by the same trained nurse. Height was measured in the
supine position until 2 years of age (Holtain LTD, Crymych, Pembs, United Kingdom),
and later with a Harpenden stadiometer (Holtain LTD, Crymych Dyfed, United
Kingdom). The height standard deviation score (hSDS) was calculated according to the
following equation: hSDS = (observed value – mean value) / SD, where SD represents the
standard deviation for the normal population of the same chronological age and gender
(142, 143). In study I, the ∆hSDS was calculated from height measurements performed 6
months before and after the dialysis began, and in study III nine months after the study
began. The patients’ height percentiles were calculated according to the Finnish reference
data (V) (144).
Blood pressure measurement (V)
Mean daytime systolic and diastolic blood pressures were calculated from serial blood
pressure measurements obtained with an automatic oscillometric Dinamap device (Vital
Signs monitor 1846 and 8100, Criticon inc., Tampa, FL, USA). Blood pressure was also
measured with an ambulatory blood pressure monitor over 24 hours. An auscultatory
device (QuietTrak, Tycon-Welch-Allyn, Arden, NC, USA) was used, the validity of which
has been confirmed (145). The monitor was programmed to measure blood pressure every
20 minutes during the daytime and every 30 minutes during the night. The updated 1987
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Second Task Force reference values, giving the age, gender, and height-percentile-specific
95th percentile values for systolic and diastolic daytime blood pressure, were used to
define hypertension (146). For correlation analysis, the grade of hypertension was
calculated as the difference between the patient’s BP and the 95th percentile. ABPM data
were not used to define hypertension, since the available 95th percentile values are not
applicable for patients with a body height <120 cm (104). Nocturnal declines (“dips”) in
systolic and diastolic BP were calculated from ABPM data as (mean daytime BP – mean
nightly BP) / mean daytime BP. A decline of at least 10% from the daytime BP was
considered to be normal nocturnal dipping (104, 147).
Cardiological investigation (V)
M-mode and Doppler echocardiography were performed, using an Acuson 128 XP
ultrasound unit with 4.0, 5.0, and 7.0 MHz transducers or an Acuson Sequoia ultrasound
unit with 5.0 and 7.0 MHz transducers (Acuson Corp., Mountainview, CA, USA).
Measurements were made by the same investigator (J-M.H) on an average of three
consecutive cycles, according to the recommendations of the American Society of
Echocardiography (ASE). LVM was determined by M-mode echocardiography, using the
formula for anatomic LV mass determined by the ASE-cube method (148). The following
echocardiographic data were collected: left ventricular end-diastolic diameter (LVEDD),
left ventricular end-systolic diameter (LVESD), interventricular septal diameter at end-
diastole (Sept D), left ventricular posterior wall thickness at end-diastole (LVPWD), aortic
diameter at end-diastole (AOD), left atrial diameter in systole (LAS), ejection fraction
(EF), diastolic mitral inflow measuring the peak E wave flow (early filling), and the peak A
wave flow (late filling).
Linear dimensions (LVEDD, LVESD, Sept D, LVPWD, AOD, and LAS) were
recalculated in relation to BSA0.5, as recommended by Gutgesell and Rembold (149), to
permit comparisons between the results for the age groups. Reference ranges (95th
percentile) for the echocardiographic measurements in the Dutch population were used for
the upper limit of normal (150), because they represent European reference values. For the
peak E and peak A waves, the 95th percentile values according to Schmitz et al. were
chosen (151). LVM was related to body height2.7, which produces a linear relationship and
allows comparison between the age groups (152). LVH was defined as LVM above the
95th percentile related to body height2.7 (152). We calculated the LVM (%), for correlation
analysis, as the difference between the actual LVM related to body height2.7 and 95th
percentile for LVM related to body height2.7 divided by the actual LVM related to body
height2.7.
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Atrial natriuretic peptide (ANP) measurements (V)
For ANP determinations, venous blood was taken into ice-cold tubes containing Na2
EDTA, 6 g/L of blood. Plasma was separated at 4°C and stored at –20°C until analyzed.
The ANP-C concentration was determined by radioimmunoassay without extraction
(153). The ANP-N concentration was measured from plasma with an in-house
immunoradiometric assay, using two monoclonal antibodies (Mabs). One (Mab 7801,
Medix Biochemica, Kauniainen, Finland) was used for coating maxisorp star tubes (Nunc,
Denmark), and the other (Mab 7901, Medix Biochemica) was iodinated by the
Chloramine-T method and was used as a tracer. Incubation was carried out overnight at 4-
8 °C. Calibration was made against a radioimmunoassay (RIA) method, with pro-ANP 1-
30 (Peninsula, England) as standard.  Since 1999, ANP-N has been measured from serum
by immunofluorometric assay, using two monoclonal antibodies (Mab 7901 labeled with
Europium and Mab 7801 coated microtiter plates (FB plates, Delfia-graded,
LabSystems)). Calibration was made against the RIA method, with synthetic pro-ANP 1-
30 (Peninsula, England) as standard. The ANP-N levels assayed with the two methods
were comparable.
Statistical analysis
All data are expressed as means ± 1SD, or medians (range). Comparisons of the two
groups were performed using the unpaired t test and the Mann-Whitney U test for
nonparametric data. The paired t test was used for comparison of paired measurements
from the same individual. The Wilcoxon signed rank test was used for paired comparison
of nonparametric data. Analysis of variance with repeated measures was used to determine
whether time affected the parameters studied (III), and Bonferroni’s method was used for
correction of simultaneous multiple comparisons with the baseline values within the
groups. For significant interactions, paired tests were used (III). Pearson’s correlation
coefficient was used to evaluate linear correlations between parametric data, and the
Spearman rank correlation coefficient for correlations between nonparametric data. Simple
regression analysis was used to identify the independent predictors MTAC (II), hSDS,
CCr, and urea Kt/V (III). Statistical association was considered significant at p <0.05.
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RESULTS
CLINICAL OUTCOME (I, III)
The main clinical outcome measures are summarized in Table 3. The results for children
under 5 years of age, treated between 1986 and 1994 (I), and the results for children under
5 and over 5 years of age treated between 1995 and 1999 (III) are given separately to
allow comparison. CCPD therapy consisted of 6±2 (4-12) exchanges, with a mean
volume of 730±97 ml/m2 per exchange in 1986-1994, and 9±2 (6-12) exchanges with a
mean volume of 855±188 ml/m2 per exchange in 1995-1999. The volume was lower in
the younger children; 716±95 and 982±161 ml/m2 for children under and over 5 years of
age, respectively (III). Thus, the dialysate volume per dwell was similar in children under 5
years of age treated in 1986-1994 and after 1995, but more night dwells were performed
after 1995. The total 24-h dialysate volume was significantly higher in children under 5
years of age treated after 1995 than in those treated in 1986-1994 (9.3±1.5 L/m2 vs
5.3±1.1 L/m2, p<0.0001, unpaired t test). The general outline of treatment for uremia and
the guidelines for nutrition were not changed between 1986-1994 and 1995-1999, the
essential difference being the regular use of adequacy measurements, knowledge of
peritoneal transport characteristics, and the regular use of rHuEPO. The doctors
responsible for the patients were the same in 1986-1994 and after 1995.
Hospitalization
In the 1980s, the length of hospitalization in the patients under 5 years of age was very
high, 270 days/patient-year, but decreased to 150 days/patient-year in the 1990s, after
experience with PD had increased (I). The hospitalization rate was later significantly
higher for patients under 5 years of age, as compared with older ones (III). The higher rate
of hospitalization in the younger patients was due largely to two patients with social
problems: one patient had to spend the whole dialysis period (11.2 months) in hospital,
and the other, half of the week for over 12 months. If these two children are excluded, the
length of hospitalization is reduced to 55 days/patient-year in the younger patients, and the
total length of hospitalization from 60 to 40 days/patient-year. The most common reasons
for hospitalization were dialysis control (37%) and peritonitis/ESI (15%) (III).
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Table 3.   PD outcome measures at 6 months follow-up in patients <5 years of age (1986-
1994 and 1995-1999) and in patients ≥5 years of age (1995-1999). Percentages represent
the proportions of patients with antihypertensive medication (hypertension), seizures or
pulmonary edema during at least one 3-month observation period. P1 represents the
significance level in children <5 years of age, and P2 that between children <5 and ≥5 years
of age.
____________________________________________________________________________________
<5 years ≥5 years
1986-1994 1995-1999   1995-1999 P1 P2
(n=27) (n=10) (n=9)
____________________________________________________________________________________
Age at onset 1.6±1.0 1.0±0.6 9.6±3.4
Hospitalization (days/pt.yr) 150a 95 30 0.02
Peritonitis frequency 1 : 7.3 mo 1 : 9.4 mo 1 : 15.8   
Hypertension 64% 50% 44%
Seizures 26% 0% 0%
Pulmonary edema 41% 0% 0% 0.02*
Nutrition and growth 
Protein intake (% RDA) 140 - 200%b 209±42% 178±72%
Energy intake (% RDA) 110 - 120%b 93±16% 101±41%
hSDS (6 months) -1.7±1.5 -1.1±1.1 -0.6±0.9
∆hSDS (0-6 months) +0.6±0.6 +0.8±0.6 -0.1±0.2 <0.01
Laboratory parameters 
Hemoglobin (g/L) 91±12c 104±11 118±12 0.009 0.03
Hematocrit (%) 0.27±0.04c 0.32±0.03 0.36±0.03 0.009 0.02
BUN (mmol/L) 47±15 40±6 36±8
Creatinine (µmol/L) 515±77 451±126 801±181 <0.01
Prealbumin (mg/L) 391±80 449±77 431±70
Albumin (g/L) 29±5 30±4 34±4 0.03
Protein (g/L) 54±8 60±2 63±5 0.06
Ionized Calcium (mmol/L) 1.27±0.07d 1.24±0.05 1.27±0.06
Phosphorus (mmol/L) 2.01±0.42 1.51±0.48 1.73±0.34 0.004
Intact parathyroid 389±345 163±202
hormone (ng/L)e
Medication 
Alphacalcidol (µg/wk) 1.1±2.0f 1.8±1.5 1.7±2.5
Calcium substitute (mg/kg/d) 339±163 86±48 72±17 <0.01
__________________________________________________________________________________________
* Fisher’s exact test
a
 Hospitalization (days/patient-year) between 1990-1994
b
 Analyzed for 1989-1992
c
 Patients without rHuEPO were excluded
d
 Analyzed in eight patients
e
 Data for 1986-1994 not available
f Used since 1991 in eight patients
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Peritonitis
The peritonitis rate was one episode per 7.3 patient-months during 1986–1994, and one to
9.4 patient-months during 1995–1999 for the children under 5 years of age. The
frequency for the older children was lower (one to 15.8 patient-months). Before 1995, the
culture was negative in 51% of the peritonitis episodes, and Gram-positive bacteria were
found in 26% (I). Since 1995, Gram-positive bacteria accounted for 72% of the episodes,
Gram-negative bacteria for 22%, and only 6% were culture-negative (III). The most
common bacteria both before and after 1995 was Staphylococcus aureus. Thirty-one
percent of the episodes were treated with intermittent intraperitoneal antibiotic therapy, and
the rest was treated continuously. No relapses were documented after intermittent
intraperitoneal antibiotic therapy.
Blood pressure control
Complications related to blood pressure control were clearly less numerous during the
prospective study with PD adequacy control (III) than before 1995 (I). The need for
antihypertensive medication decreased slightly as well (III). In the patients treated in 1986-
1994 and analyzed retrospectively, pulmonary edemas and seizures, related to poor blood
volume control, were numerous, but during the prospective study disappeared in both age
groups (Table 3).
Laboratory results and medication
Since the end of 1989, all patients have received rHuEPO. Prior to rHuEPO, the patients
received 12 erythrocyte transfusions per patient per year (range 8-60). The mean rHuEPO
dose was lower in the patients treated in 1989-1994 than in the younger patients treated in
1995-1999 (124±47 vs. 202±91 U/kg/wk), and accordingly their hemoglobin and
hematocrit values were lower. The younger patients needed more rHuEPO (202±91 vs.
139±101 U/kg/wk) (III). When the results in children under 5 years of age are compared,
BUN, serum creatinine, prealbumin, protein, and phosphorus levels are seen to have
improved (Table 3). With intensified clinical care and PD adequacy control, the laboratory
results did not differ significantly between the age groups, with the exception of serum
albumin, which remained significantly lower in the younger patients (p<0.05 at  3, 6 and 9
months, unpaired t test) (III). Although the younger patients had higher alphacalcidol
substitution (2.2 vs. 1.3 µg/week), their intact PTH concentration was higher (difference
not significant) after the baseline (III). The need for calcium substitution decreased
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significantly in the younger patients after 1995 (from 339 to 86 mg/kg/d), and did not
differ later between the age groups under and over 5 years of age.
Nutrition and growth
In the retrospective analysis, between 1989-1992, the protein and energy intakes of some
patients were analyzed (154). Protein intake was higher during the prospective study, but
energy intake was lower, as seen in Table 3. No significant difference in nutrition was
found between the age groups (III). During 1986-1994, most of the children showed
catch-up growth: the mean 6-month change in height decreased by –0.12±068 SDS prior
to dialysis, and increased by +0.59±0.64 SDS after dialysis began (p<0.001, Wilcoxon
signed rank test). The increase in hSDS was better in the 29 nephrectomized patients
between 1986–1994 (Figure 3). One of the nephrectomized and one of the non-
nephrectomized patients, studied retrospectively, were treated with rhGH. During the
prospective study, all the younger patients and 33% of the older patients (one patient was
treated with rhGH) showed catch-up growth. The nine-month change (baseline to 9 month
follow-up) in hSDS was +0.97±0.71 for the children under 5 years of age, and
–0.04±0.23 for the children over 5 years of age (p=0.002, Mann-Whitney U test) (Figure
3). In simple regression analysis hSDS was not significantly predicted by urea Kt/V, CCr,
energy, or protein intake (/kg, /m2, or as a percentage of RDA), serum albumin, serum
protein, phosphorus, BUN, intact PTH, or serum alkaline phosphatase (III). However,
trends toward positive prediction of hSDS by CCr and negative prediction by alkaline
phosphatase were observed.
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Figure 3.  Height standard deviation score (hSDS) in 1986-1994 for 29 nephrectomized
and 5 non-nephrectomized patients <5 years of age, and in 1995-1999 for 10 patients <5
years and 11 patients ≥5 years of age. Dialysis months represents the observation period in
months, and the shaded area the normal growth range (±2SDS) for Finnish children.
PERITONEAL TRANSPORT KINETICS  (II)
Peritoneal transport kinetics were studied in 28 patients, 10 of whom were under 5 years
of age. Seven children had histories of peritonitis 2.8±1.6 months prior to their initial
PET.  The mean dialysis time prior to initial PET did not differ significantly between the
age groups, or between children who had had or had not had peritonitis. No significant
difference in equilibration was found between children who had had or had not had
peritonitis. Therefore, all initial PETs were pooled. In Table 4, D/P and D/D0 glucose
values at 1 and 4 hours are given for all patients and subgroups of children under 5 and
<5 years
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over 5 years of age. No significant difference in membrane transport was found between
the two age groups. The mean test volume was 967±31 ml/m2 in the younger age group
(n=10) and 994±23 ml/m2 in the older age group (n=18) (p=0.03, Mann-Whitney U test).
Table 4.  Initial PET data at 1 and 4 hours (mean D/P±1SD) for
the total of 28 children, and for children <5 and ≥5 years (yrs) of
age (n=10 and n=18, respectively).
__________________________________________________
1 hour 4 hours
__________________________________________________
Urea Total 0.49±0.08 0.92±0.05
<5 yrs 0.50±0.07 0.93±0.03
≥5 yrs 0.49±0.09 0.91±0.06
Creatinine Total 0.32±0.08 0.70±0.12
<5 yrs 0.34±0.04 0.70±0.09
≥5 yrs 0.31±0.09 0.70±0.14
Glucose Total 0.69±0.07 0.32±0.10
<5 yrs 0.67±0.05 0.30±0.08
≥5 yrs 0.70±0.08 0.33±0.11
Sodium Total 0.84±0.04 0.86±0.04
<5 yrs 0.86±0.04 0.86±0.05
≥5 yrs 0.83±0.04 0.86±0.04
Potassium Total 0.50±0.11 0.85±0.11
<5 yrs 0.49±0.06 0.83±0.10
≥5 yrs 0.50±0.12 0.85±0.12
Phosphate Total 0.26±0.09 0.57±0.12
<5 yrs 0.26±0.04 0.59±0.13
≥5 yrs 0.26±0.10 0.56±0.12
Albumin Total 0.005±0.003 0.014±0.007
<5 yrs 0.005±0.002 0.014±0.006
≥5 yrs 0.005±0.003 0.014±0.008
_____________________________________________________________
Longitudinal changes in peritoneal membrane transport
A final PET was performed in 21 patients (nine patients were under 5 years of age and 12
over 5 years of age) at a mean of 0.8±0.4 years after the initial PET. The mean test volume
in the final PET was 1005±20 ml/m2, (1009±56 and 1002±13 ml/m2, difference not
significant, respectively). No significant difference was found in membrane transport
when the initial and final PETs were compared (Figure 4).
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Figure 4.  Mean initial and final 1-, 2-, and 4-hour D/P ratios for urea, creatinine,
phosphate, sodium, and potassium, and the D/D0 glucose ratio, respectively. The gray bars
represent initial PET of 28 patients, and the black bars the final PET of 21 patients.
No significant changes in equilibration rates were observed in patients who had
experienced one or more peritonitis episodes between the initial and final PET (n=8), and
in those without peritonitis (n=13). The time interval between the PETs did not differ
significantly between the groups. In the peritonitis group, the equilibration ratio decreased
only in one patient with two peritonitis episodes caused by Pseudomonas aeruginosa (her
initial and final 4-h D/P creatinine values were 0.76 and 0.60).
Baseline peritoneal membrane permeability was slightly higher in the patients with CNF
(n=10) than in the non-CNF patients. However, this difference was significant only for the
baseline 4-h D/D0 ratio for glucose (0.26±0.06 and 0.35±0.10, p=0.03, unpaired t test)
and the 4-h D/P ratio for phosphate (0.65±0.12 and 0.53±0.11, p=0.01, unpaired t test).
In the final PET, these differences in membrane transport were reduced or had
disappeared. Patients with CNF did not differ from other patients in respect of test volume
or dialysis time prior to the study.
Mass transfer area coefficient
The MTAC data for urea, creatinine, glucose, and albumin are given in Table 5. No
difference was found in MTAC between the children under and over 5 years of age, nor
was any correlation found between MTAC and age. When all MTAC values were pooled,
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no significant longitudinal changes were observed, but the children with a history of
peritonitis tended to have higher MTACs.
Table 5.  Mass transfer area coefficients (mean±1SD, ml/min/1.73m2) calculated
for 28 children and for the subgroups of children <5 years of age (n=10) and
≥5 years of age (n=18).
________________________________________________________________________
Urea Creatinine Glucose Albumin
________________________________________________________________________
Total 22.3±4.8 10.9±4.1 11.1±3.3 0.07±0.03
<5 years 22.5±2.4 10.4±2.8 11.5±2.9 0.07±0.02
≥5 years 22.2±5.8 11.3±4.7 10.9±3.5 0.08±0.03
________________________________________________________________________
DIALYSIS ADEQUACY (III)
Adequacy was measured from 24-h dialysate and urine collection. If the clearance targets
(Kt/V >2 and CCr >60 L/wk/1.73m2) were not reached, the dialysis prescription was
optimized with the help of the PD ADEQUEST computer program and knowledge of the
peritoneal transport characteristics, in order to increase clearances. The mean urea Kt/V
and CCr values at baseline and at 9 months are listed in Table 6. Urea Kt/V did not change
during the 9-month observation period, nor was any significant difference found between
the two age groups. Every patient reached urea Kt/V >2.0. The mean CCr increased slightly
during the 9-month period. It differed significantly between the age groups only at
baseline (Table 6). At baseline, CCr was <60 L/wk/1.73 m2 in 70% of the patients under 5
years of age, and at 9 months in 29%. All the older patients attained a CCr >60 L/wk/1.73
m2. Residual renal clearance decreased slightly during the study period (from 2.9 to 2.4
ml/min/1.73 m2). Urea Kt/V and CCr were correlated significantly (r=0.61, p<0.05 at
baseline, Spearman rank correlation). In simple regression analysis, neither urea Kt/V nor
CCr  were predicted by age, BUN, serum albumin, protein intake, or energy intake. The
total daily dialysate volume (ml/m2) gave a weak positive prediction of urea Kt/V and CCr.
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Table 6.  Mean weekly urea Kt/V and CCr (mean ±1SD) at the beginning of the study,
and after 9 months on PD for 21 children and for the subgroups of children <5 years
of age (n=10) and ≥5 years of age (n=11).
________________________________________________________________
All <5 yr ≥5 yr  p*
________________________________________________________________
Kt/V
baseline 3.2±0.5 3.1±0.6 3.2±0.4
9 months 3.2±0.5 3.3±0.5 3.0±0.4
CCr (L/wk/1.73m2)
baseline 68.8±16.6 58.7±11.9 78.0±14.9 0.004
9 months 71.3±14.0 71.2±19.9 71.5±7.3
________________________________________________________________
*  Comparison of different age groups, Mann-Whitney U test.
TIDAL PERITONEAL DIALYSIS  (IV)
Dialysis efficacy with CCPD and TPD was analyzed in 13 patients, five of whom were
under 5 years of age. In most of the patients, in contrast to our initial expectations,
prediction of UF during TPD was relatively easy and alarms caused by volumes that were
too low diminished within 2 to 4 weeks. Patients and parents felt safe and familiar with
TPD after a few weeks, and no patients reported dialysis-induced pain during TPD, in
contrast to three patients (23%) during CCPD.  
Table 7.  Description of dialysis regimens in 13 patients with continuous cycling
peritoneal dialysis (CCPD) and with tidal peritoneal dialysis (TPD).
__________________________________________________________________
CCPD TPD p
__________________________________________________________________
Number of dwells/night 9±1 22±2 0.005
Dialysis time/night (h) 9.7±0.9 9.4±0.9
Volume/dwell period (ml/m2) 888±128 951±129
Night volume (ml/m2) 7956±924 11365±1165 0.001
Dialysate flow rate/night (ml/kg/h) 32.7±4.6 46.4±3.7 <0.001
Ultrafiltration rate/night (ml/m2) 495±251 447±215
Glucose content (%) 1.8±0.4 1.6±0.2 0.01
____________________________________________________________________
43
Dialysis prescriptions with CCPD and TPD are listed in Table 7.  Both the total nightly
dialysate volume (ml/m2) and the nightly dialysate flow rate (ml/m2/h) were significantly
higher with TPD than with CCPD.
The mean total CCr was significantly higher with TPD than with CCPD (p=0.02,
Wilcoxon signed rank test), while the mean total urea Kt/V did not differ significantly
(Table 8). With TPD, the mean total weekly CCr and urea Kt/V were clearly higher in
patients with high than in those with high average membrane permeability for creatinine
(Table 8), although there were no significant differences in dialysis prescriptions between
high and high average transporters during TPD and CCPD. During CCPD, no such
difference was found.
Table 8.  Total weekly urea Kt/V and creatinine clearance (CCr) in 13 patients on CCPD
and TPD. Urea Kt/V and CCr were also analyzed for high (H; n=3 and n=2 with CCPD
and TPD, respectively) and high-average (HA; n= 10 and n=11 with CCPD and TPD)
membrane transporters (based on 4-h D/P of creatinine).
__________________________________________________________________
Kt/V CCr
                     ______________        ______________
CCPD TPD p CCPD TPD p
__________________________________________________________________
All patients 3.3±0.4 3.5±0.5 72.5±16.0 79.3±18.5 0.02
HA transporters 3.3±0.4 3.3±0.5 73.9±17.0 74.8±16.0
H transporters 3.4±0.6  4.1±0.01 68.0±15.0 103.8±11.3
__________________________________________________________________
In patients under and over 5 years of age, no significant difference was found between
CCPD and TPD either in total CCr or in total urea Kt/V. No difference was found between
the age groups either, when clearances achieved with CCPD or TPD were compared.
During both CCPD and TPD, the nightly dialysis time was significantly longer and the
nightly dialysate volume significantly lower in the children under 5 years of age (Table 9),
which can be attributed to the larger number of nephrectomized CNF patients in this age
group (80% vs. 25%). The dialysate volume was increased slowly in these patients, as
CNF patients are more prone to fluid leaks because of muscular hypotonia. However,
regardless of the lower fill volume and longer nightly dialysis time, the number of cycles
per hour and the total dialysis volume per night (ml/m2) did not differ significantly
between the age groups during either CCPD or TPD.
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Table 9.  Description of dialysis regimen and total weekly urea Kt/V and
creatinine clearance (CCr) for patients under and over 5 years of age with
CCPD and TPD.
___________________________________________________________
<5 years ≥5 years p
(n=5) (n=8)
     ___________________________________________________________
  Dwells/night CCPD 10.2±1.1 8.4±1.1 0.02
TPD 22.4±1.7 21.7±2.3
Dialysis time CCPD 10.5±0.6 9.2±0.6 0.01
(h) TPD 9.9±0.7 9.1±0.9 0.05
Volume/dwell CCPD 773±61 961±102 0.003
(ml/m2) TPD 869±81 1003±130 0.04
Kt/V CCPD 3.4±0.6 3.2±0.4
TPD 3.4±0.6 3.5±0.6
CCr CCPD 63±16 79±13
(L/wk/1.73m2) TPD 68±17 86±16 0.06
___________________________________________________________
Albumin and phosphate losses into the dialysate did not differ significantly between
CCPD and TPD (data obtained from five patients). The total albumin loss was 2.2±0.5
g/m2 during CCPD and 2.3±0.7 g/m2 during TPD, and the phosphate losses 6.0±1.6 and
5.9±2.3 mmol/m2, respectively. Patients under 5 years of age lost more albumin both
during CCPD and TPD than the older patients (difference not significant). The phosphate
loss did not differ between the age groups during CCPD or TPD.
HYPERVOLEMIA AND HYPERTENSION (V)
Hypertension
The cardiopulmonary status, ANP, and the prevalence of high BP were analyzed in 21
patients (11 patients were under 5 years of age), the aim being to specify the impact of
hypervolemia on the etiology of high blood pressure and to facilitate the diagnosis of
hypervolemia. The role of hypervolemia in the etiology of high blood pressure was
especially studied in 13 nephrectomized patients, as renal causes of hypertension could be
excluded. ANP-C and ANP-N were measured as possible additional markers of
hypervolemia.
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Of all patients, 52% were treated with antihypertensive drugs at baseline (54% of the
younger and 50% of the older patients). Calcium channel blockers and ß-adrenergic
blockers were the drugs most commonly used, followed by ACE inhibitors. Of the treated
patients, 82% had the mean daytime systolic BP (sBP) and the mean daytime diastolic BP
(dBP) above the 95th percentile, and their BP was significantly higher than that of patients
without antihypertensive treatment (p=0.003 for sBP and p=0.0004 for dBP, Mann-
Whitney U test).
The mean daytime BPs (Dinamap vs. ABPM) for all patients are given in Table 10. In
52% of the patients the mean sBP and in 43% the mean dBP were above the 95th
percentile (73% and 100% were receiving antihypertensive medication, respectively). In
these hypertensive patients, the mean difference between sBP and the 95th percentile was
31±19 mmHg (range 3-58 mmHg), and between dBP and the 95th percentile 24±11
mmHg (range 5-35 mmHg). More patients under 5 years of age had hypertension than
those over 5 years of age. In the younger patients daytime sBP and dBP were above the
95th percentile in 73% and 54%, respectively, as compared with 30% and 30% in the older
patients. However, the mean differences between the BP and the 95th percentile were
higher in the older patients (35±16 and 29±21 mmHg for sBP, difference not significant,
and 26±14 and 22±11 mmHg for dBP, difference not significant, respectively). The
nightly decline in BP (“nocturnal dip”) for all patients and for the age groups separately
are also presented in Table 10. The nocturnal dip was less in the nephrectomized than in
the non-nephrectomized children (5±10% vs 13±6% in sBP, difference not significant,
and 10±14% vs. 14±11% in dBP, difference not significant, respectively). If a nightly
decline of 10% or more is considered normal, 53% were nondippers for dBP, and 40%
for sBP.
Atrial natriuretic peptide
The mean plasma level of ANP-C at baseline, measured in the morning after PD, was
135±120 pg/ml (8.5-448 pg/ml) for all patients. The corresponding values for patients
under and over 5 years of age were 147±151 pg/ml and 122±79 pg/ml (difference not
significant, Mann Whitney U test). The mean ANP-N was 3.6±3.2 nmol/L (0.4-12.0
nmol/L) for all patients. The values for the two age groups were 4.3±3.7 nmol/L and
2.7±2.4 nmol/L (difference not significant, Mann Whitney U test), respectively. ANP-C
and ANP-N correlated significantly (r=0.60, p=0.01, Spearman rank correlation).
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Table 10.  Mean daytime blood pressures (BPs) measured with an automatic
oscillometric device (Dinamap) and with an ambulatory blood pressure monitor
(ABPM) in 21 patients on chronic peritoneal dialysis. Nocturnal decline is given
in % for 15 patients. The number of patients is given in parentheses.
__________________________________________________________________
All patients    <5 years   ≥5 years
__________________________________________________________________
Systolic BP
  Dinamap, mmHg 118±30 (21) 114±35 (11) 123±23 (10)
  ABPM, mmHg 120±18 (16) 121±19 ( 7 ) 119±19 ( 9 )
  Nocturnal decline, %   10±10 (15)     7±14  ( 6 ) 12±6  ( 9 )
Diastolic BP
  Dinamap, mmHg 67±24 (21) 61±25 (11) 74±23 (10)
  ABPM, mmHg 73±14 (16) 70±12 ( 7 ) 75±15  ( 9 )
  Nocturnal decline, % 13±12 (15) 14±16 ( 6 ) 12±10  ( 9 )
__________________________________________________________________
Cardiac findings
Cardiac measurements are listed in Table 11. None of the patients had structural cardiac
abnormalities. Left ventricular and atrial internal dimensions were above the 95th percentile
in less than 20% of the patients, and no difference was found between the age groups. In
contrast, wall thickness measurements (Sept D and LVPWD) and also AOD were above
the 95th percentile in approximately 30% of the patients, more often in the younger
patients. When related to BSA0.5, Sept D and LVPWD were significantly greater in the
younger patients. Forty-five percent of the patients had LVM related to body height2.7
above the 95th percentile. LVH was significantly greater in the younger patients. Left
ventricular systolic function (EF,%) and diastolic function (peak E and A wave) were not
significantly impaired.
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Table 11.  Baseline cardiopulmonary status of  21 patients on chronic peritoneal
dialysis. Values are also given as means ±1SD separately for 11 patients <5 and 10
patients ≥5 years of age.
__________________________________________________________________
all < 5 years ≥ 5 years p *
__________________________________________________________________
LVEDD
    > 95th centile,   % 5 9 0
    LVEDD / BSA0.5 40.0±5.4 40.2±6.9 39.8±3.4
LVESD
   > 95th centile,  % 19 18 20
    LVESD / BSA0.5 26.1±5.8 27.0±7.1 25.1±4.0
Sept D
   > 95th centile,  % 35 70 0
  Sept D / BSA0.5 7.4±1.6 8.4±1.5 6.5±1.2 0.007
LVPWD
   > 95th centile,  % 24 36 10
  LVPWD / BSA0.5 7.3±1.8 8.3±1.7 6.3±1.3 0.01
AOD
  > 95th centile,  % 31 60 12
  AOD / BSA0.5 22.5±2.4 23.1±1.9 22.1±2.6
LAS
   > 95th centile,  % 0 0 0
  LAS / BSA0.5 27.5±4.4 30.2±4.0 25.7±3.9
LVM
  > 95th centile,  % 45 60 30
  LVM / height2.7, g/m2.7  53.5±28.2 70.5±30.7 36.5±9.9 0.008
EF,  % 65±9 63±11 66±7
__________________________________________________________________
* p, when results for patients under and over 5 years of age are compared.
LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter;
Sept D, interventricular septal diameter at end-diastole; LVPWD, left ventricular posterior wall
thickness at end-diastole; AOD, aortic diameter in end-diastole; LAS, left atrial diameter in systole;
LVM, left ventricular mass; EF, ejection fraction
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Correlations between hypertension, ANP, and cardiac findings
LVM (%) correlated significantly with the severity of hypertension, calculated from the
mean systolic daytime BP (r=0.79, p<0.001, Spearman rank correlation), and with ANP-N
(r=0.66, p=0,005, Spearman  rank correlation). ANP-N correlated significantly with the
severity of hypertension (r=0.82, p<0.001, Spearman rank correlation). ANP-C also
correlated significantly with the severity of hypertension (r=0.66, p=0.005, Spearman rank
correlation), but less strongly than ANP-N.
In 61% of the 13 nephrectomized patients, the difference between BP and the 95th
percentile for BP was positive, indicating hypertension. A clear association was seen
between LVH, ANP-N, and the severity of hypertension (mean daytime sBP) in the
patients with ANP-N >3.0 nmol/L (Table 12).
Table 12.  Characterization of the 12 of the 13 nephrectomized patients. Post-
nephrectomy (Post-nephr) represents the time in years between nephrectomy and
the study. Hypertension represents the difference between a patient’s mean daytime
systolic BP and the reference BP (95th percentile).
_________________________________________________________________
Age Post-nephr LVM ANP-C ANP-N Hypertension
(years) (years) (%) (pg/ml) (nmol/L) (mmHg)
_________________________________________________________________
1. 1.85 0.91 +57.0 378 9.70 +52
2. 0.61 0.01 +37.1 85 3.80 +11
3. 0.73 0.05 +37.0 448 12.00 +47
4. 0.52 0.01 +25.6 46 3.50 +15
5. 1.66 1.06 +21.7 197 5.10 +58
6. 0.69 0.03 +21.7 76 3.74 +29
7. 8.63 0.02 +16.1 178 3.40 +43
8. 1.68 1.01 -23.5 29 1.70 +  3
9. 7.25 2.78 -24.4 118 1.80 -10
10. 0.51 0.02 -24.4 142 1.45 -26
11. 0.87 0.01 -55.7 33 1.60 -38
12. 8.21 0.25 -63.6 8.5 2.10 -11
_________________________________________________________________
LVM, left ventricular mass; ANP-C, C-terminal atrial natriuretic peptide;
ANP-N, N-terminal atrial natriuretic peptide 
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Echocardiography as well as BP and ANP measurements were repeated in nine patients
after 0.9±0.2 years. In the repeated echocardiography, the prevalence of LVH decreased
from 50% to 11%. BP also decreased (sBP from 127 to 115 mmHg, and dBP from 80 to
63 mmHg), as well as ANP-C (from 150 to 128 pg/ml) and ANP-N (from 3.4 to 2.4
nmol/L). However, none of these changes were significant. At baseline, seven of the nine
patients were being treated with antihypertensive drugs, but, when the measurements were
repeated, only three.
50
DISCUSSION
The present study was undertaken to evaluate the outcome in children treated with chronic
PD with intensified clinical care and a controlled dialysis dose, and further to compare the
results with those of patients under 5 years of age treated previously. Additionally,
utilization of TPD in children and the role of hypervolemia in the etiology of high blood
pressure were studied. The efficacy of PD did not differ significantly between TPD and
CCPD. Peritoneal transport kinetics were comparable in children under and over 5 years
of age. The clinical outcome of patients under 5 years of age, studied after 1995, improved
under PD adequacy control, compared with the previous results in children of the same
age. According to the literature, the outcome of PD in young children is not as good as in
older children or adults. However, the outcome in the patients under and over 5 years of
age in this study did not differ significantly, although the frequency of peritonitis and the
prevalence of high blood pressure, mainly caused by increased blood volume, remained
somewhat higher in the younger patients. For the first time, catch-up growth was achieved
without rhGH in most children during PD.
CLINICAL OUTCOME AND ADEQUACY OF DIALYSIS
Information about the effects of PD adequacy measurements on clinical outcome in
children is scanty. In most dialysis centers, PD prescription is still empirical and mainly
aimed at optimizing daily ultrafiltration and correcting uremia. To improve the outcome,
we optimized the PD prescription with the help of knowledge of the peritoneal membrane
capacity and dialysis adequacy in our patients. Since mortality in pediatric PD patients is
low, we measured the more sensitive parameters of patient morbidity, such as growth,
nutritional parameters, and serum albumin, as indicators of patient well-being. Dialysis
adequacy differed between the age groups only at baseline with respect of CCr. Neither
urea Kt/V nor CCr predicted serum albumin or nutritional parameters, but there was a trend
toward positive prediction of hSDS by CCr.
Values of urea Kt/V and CCr in the patients studied were approximately 13% and
15% higher than during the patients’ regular dialysis program, because we modified the
24-h dialysate collection to make it possible to keep the patients only 2 days in hospital
during the PET and adequacy studies. Thus, after recalculation, our urea Kt/V
approximates 2.8, and CCr 61 L/wk/1.73 m2. Especially in our young nephrectomized
patients the DOQI target CCr of >60 L/wk/1.73 m2 was hard to achieve. Schaefer et al.
found CCr and urea Kt/V values similar to ours in their patients, and also reported that it
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was difficult to achieve CCr targets. Recently, van der Voort et al. reported that only 45% of
their 20 pediatric patients had a dialytic Kt/V and 10% dialytic CCr above the DOQI
guidelines (155). All their patients were well dialyzed. They had a dwell volume >1000
ml/m2 and a nightly dialysis time of at least 10 hours, and 17 patients had an additional
long day dwell. In contrast to our findings and those of Schaefer et al. and van der Voort
et al., Walk et al. reported a mean total CCr of 74±47 L/wk/1.73m2 and a mean total urea
Kt/V of 2.3 in their 19 children on PD (69). The high CCr in their patients can be
explained by the relatively high residual renal function (<10 ml/min/1.73m2 compared with
<3 ml/min/1.73m2 in our patients) in their 12 non-nephrectomized patients; in their
nephrectomized patients the mean CCr was only 42 L/wk/1.73m2. Thus, it seems that in
most nephrectomized patients the DOQI target of CCr >60 L/wk/1.73m2 is hard to reach.
Growth is one of the most important end points of PD outcome in children. Despite
improved control of nutritional intakes, acidosis, disturbed calcium/phosphorus balance
and uremia, poor growth has remained a major problem during PD treatment (14, 17).
Catch-up growth has mostly been reached only with rhGH therapy (17, 90). The first
prospective pediatric report on the effects of PD adequacy control was published in 1999,
and included 51 children followed for 18 months (68). In that study, growth was slightly
retarded, although 37% of the patients were treated with rhGH. In contrast to previous
reports, both our retrospectively and prospectively studied patients showed significant
catch-up growth. Growth was significantly better in the younger patients, partly because of
normalization of the protein balance after nephrectomy in the patients with CNF.
Compared with our retrospective study of patients treated between 1986 and 1994 (I), the
hSDS at 6 months and the 6-month ∆hSDS in patients under 5 years of age were better
after 1995 (III), when strict dietary control and PD adequacy studies were included,
although the numbers of nephrectomized patients with CNF were similar. There was a
trend toward prediction of hSDS by CCr. Thus, our findings suggest a positive effect of
strict dietary and PD adequacy control on growth, bearing in mind that the number of
patients and the follow-up period are limited. Schaefer et al. (68) reported a weak positive
effect of dialytic small solute clearance on statural growth, which supports our results.  
The number of culture-negative findings in peritonitis diagnoses decreased from 51%
between 1986-1994 to 6% after 1995. The high proportion of negative cultures may have
been due to the prompt antibacterial treatment in suspected cases of peritonitis before
1995. Since 1995, we have centrifuged an aliquot of the dialysis sample before examining
with Gram’s stain and before culturing the effluent. This may further have improved the
diagnosis in patients treated for peritonitis at the Hospital for Children and Adolescents,
University of Helsinki (31% of the study patients).
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The overall frequency of peritonitis and exit-site infections decreased slightly in
children under 5 years of age treated after 1995 under PD adequacy control. However, the
frequency of peritonitis was higher in the younger patients, which agrees with previous
reports on peritonitis frequency (37, 65, 66, 94). In Italy and in Japan, lower incidences of
peritonitis (one to 26–28 patient-months) have been reported (64, 65). However, according
to the 1996 NAPRTCS registry data (37), the overall frequency of peritonitis was one per
13 patient-months in North American PD patients. Our results are similar (one per 11.6
patient-months), although most of our patients had single-cuff Tenckhoff catheter with
exit-site pointed up, which has been found to increase the risk of peritonitis (66).
Since, in PD patients, the peritoneum is an immunocompromised site, with access to
an external world filled with different organisms, complete avoidance of peritonitis
episodes will not be possible. It has been suggested that the low pH of fresh dialysis fluid
reduces opsonic activity, and that the combination of low pH, lactate, and the
hyperosmolality of peritoneal dialysis solutions impairs immune cell function, at least in
vitro (156). Dialysis fluid also has a diluting effect on macrophages, opsonins, and
immunoglobulins, which further attenuates the host defense. Thus, PD forms with long
dwells have been suggested to decrease peritonitis frequency because of the reduced
diluting effect, bearing in mind the importance reducing the risk of touch contamination
(64). As our patients are on CCPD with frequent exchanges and with 1-3 exchanges per
day, the short dwells with a large amount of fresh dialysis fluid might be a risk factor
increasing the peritonitis rate. Another risk factor might be the manual day exchanges,
which increase the risk of touch contamination in our patients. To lower the peritonitis
frequency, the use of a downward exit-site and two cuffs in the catheter has been
suggested (37). Prophylactic control with a Staphylococcus aureus nasal carriage might
also be beneficial in preventing ESI and peritonitis in our patients (157, 158), as
Staphylococcus aureus is the most common bacterium causing peritonitis in our patients.
PERITONEAL TRANSPORT KINETICS
The possibility of differences in peritoneal transport kinetics was evaluated over time and
between children under and over 5 years of age. No changes were found in peritoneal
membrane transport function during the follow-up period, and peritoneal transport kinetics
(D/P and MTAC) was found to be independent of age. There was neither a significant
difference between the patients under and over 5 years of age nor a correlation with age.
Peritoneal membrane transport has been reported to be higher in small children when the
test volume is related to weight instead of BSA (6-11). Even when relating the PET
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volume to BSA, the initial studies reported a tendency toward more rapid transport in the
youngest patients (55, 56). Since 1996, findings similar to ours have been reported (12,
13). Warady et al. showed that the peritoneal equilibration rate did not differ between
children of different ages, but MTACs for glucose and creatinine were higher in infants
than in older children (12). They suggested that higher MTACs might be the result of
maturational changes in the peritoneal membrane or differences in the effective peritoneal
membrane surface area. Since 1996, the PET results reported by them have been used as
pediatric reference values. Recently, Bouts et al. found neither any correlation between
D/P or MTAC and age in 18 pediatric PD patients nor any differences between pediatric
and adult results (159). MTAC should be independent of differences in dialysate volume
(160) and in the glucose content of dialysis fluids (161). Thus, the variable test volumes
(910-1500 ml/m2 vs. 1100 ml/m2) and lower glucose content of the fluid (1.36% vs.
2.27%) used by Bouts et al. as compared with that used by Warady et al. do not explain
the discrepancy in MTAC related to age between these two studies (12, 159). The results
of Bouts et al. can be interpreted to support our findings.
Compared with the reference data of Warady et al. (12), our patients had higher membrane
transport for urea, potassium, and creatinine at 4 hours (0.91±0.05 vs. 0,82±0.09 and
0.85±0.11 vs. 0.75±0.10 and 0.70±0.12 vs. 0.64±0.13, respectively). Our higher D/P
values could partly be explained by the higher peritoneal membrane transport and the
slightly lower test volume at baseline PET in our patients with CNF. It should also be
noticed that the mean dialysis time prior to the PET measurements was clearly shorter in
our patients (0.4±0.4 vs. 2.0±1.1 years) (12).
In the present study, the CNF patients showed higher peritoneal membrane
permeability (D/P and MTAC) in the initial PET, but this difference disappeared in the
final PET. However, there was no difference in the test volume or the dialysis time
between the CNF patients and the other patients. CNF is caused by a defect in the NPHS1
gene encoding a transmembrane protein, called nephrin (3), which appears to be expressed
solely in glomerular podocytes. There is no evidence of expression of nephrin in the
peritoneal membrane (J.Patrakka et al., unpublished data, 2000). Thus, the peritoneal
membrane in these patients should be intact. In support of this, de Boer at al. found no
size selectivity in peritoneal membrane transport in children with CNS as compared with
non-CNS patients (162). CNF patients have low serum albumin, prealbumin, and protein
levels prior to nephrectomy. They also have cholesterol, lipoprotein, and phospholipid
abnormalities. Prealbumin normalizes after 1 month on PD, and albumin, protein,
cholesterol, and lipoprotein levels improve substantially within 3 months, but do not reach
normal values (154). In addition, children with CNF, in contrast to other patients, become
uremic only after nephrectomy. These metabolic differences may have an impact on
membrane permeability, especially during the first months on PD, which could partly
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explain the higher peritoneal equilibration rate in our patients compared to the reference
data (12).
TIDAL PERITONEAL DIALYSIS
Preliminary results indicated that TPD was able to provide a dialysis outcome equal to that
of CCPD within a shorter time (18, 19). We started the study by comparing dialysis
adequacy in the same patients treated with CCPD and TPD, with the aim of discovering
whether TPD could provide better dialysis adequacy than CCPD. Our results showed that
TPD is an adequate method for dialysis in pediatric patients, including infants, with
ESRD. No significant difference in adequacy of dialysis was found between the age
groups under and over 5 years of age during TPD. However, TPD, because of the better
osmotic gradient (163), provided similar UF with a lower glucose content than CCPD.
When the results for all patients or for the different age groups were compared, it
appeared that, despite a 42% higher flow rate during TPD, albumin and phosphate losses
were not higher during TPD than during CCPD. However, we must emphasize that TPD
was performed with a moderate dialysate flow rate (<50 ml/kg/h) and albumin and
phosphate losses were studied only in five patients.
 In the initial TPD studies, Flanigan et al. showed that, when dialysate flow rate was
increased from 30 to 50 ml/kg/h, urea Kt/V and CCr increased, but the dialysate pattern did
not alter TPD efficacy (48). To achieve solute removal equal to CCPD, some of their
patients needed a TPD flow rate as high as 60-70 ml/kg/h. They suggested that, when a
dialysate volume sufficiently large to cover the peritoneal membrane was used, the dialysis
efficacy was determined by peritoneal membrane permeability and the dialysate flow rate
(48). Thus, to achieve the same solute removal in a patient with low peritoneal membrane
permeability, a higher flow rate is needed. In 1996, Durand et al. defined the maximal
effective dialysate flow rate (MEDF) as the hourly dialysate flow rate giving the maximum
peritoneal creatinine clearance, beyond which peritoneal clearances decrease when the flow
rate is further increased (164). In six adult patients, they showed that MEDF depends
strictly on peritoneal permeability: MEDF was 1.8 L/h with TPD for a low transporter (4-
h D/P creatinine 0.50) and 4.2 L/h for a high transporter (4-h D/P creatinine 0.80). For an
adult weighing 60 kg, these rates correspond to approximately 30 ml/kg/h and 70 ml/kg/h.
Thus, MEDF is higher for the high transporters than for the low transporters.
Accordingly, after MEDF is reached in low transporters, it is possible to obtain clearances
equal to those of high transporters only by increasing the dialysis time (164).
In our study, both CCPD and TPD were performed with a moderate flow (<50
ml/kg/h). TPD, with a moderate, 42% higher dialysate flow rate and slightly shorter
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nightly dialysis time, was superior to CCPD only in the high transporters, which is in
accord with the findings of Durand et al. (164). Several recent studies have also confirmed
these findings. In 1995, Edefonti et al. showed TPD with a high flow rate (68 ml/kg/h) to
be superior to NIPD with a low flow rate (29 ml/kg/h) (20). Patients with H/HA
membrane permeability seemed to be more suitable for TPD than those with L/LA
peritoneal membrane permeability (20), as we also found. In 1999, Vychytil et al. showed,
that in adult patients TPD did not provide better small-solute or middle-molecule
clearances than intermittent peritoneal dialysis up to a dialysate flow rate of 3 L/h (which
approximates 50 ml/kg/h in an adult patient with a body weight of 60 kg) (49).
Thus, TPD, besides CCPD is a good option in pediatric PD patients. Both TPD and
CCPD provided adequate dialysis in our patients, but less drainage-induced pain was
reported during TPD. But whether TPD is superior to CCPD depends on the patient’s
transporter state, and because of its higher costs (about $400 higher per month in our
study), TPD should be saved for patients with high membrane permeability and reduced
ultrafiltration, and for patients with mechanical outflow problems or outflow pain.
BLOOD VOLUME CONTROL
As high blood pressure was common in our patients, we initiated the hypertension study
to assess the cardiopulmonary status and the prevalence of hypertension in our PD
patients, and to further specify the impact of hypervolemia in the etiology of high BP.
ANP was measured as a possible additional marker of hypervolemia.
 Hypertension was found in 52% of our patients. It was more common in our
younger and nephrectomized patients. In previous reports, about 50% of pediatric PD
patients, according to their need for antihypertensive medication, have been defined as
having hypertension (14). There are few reports of BP measurements in pediatric PD
patients. Lingens et al. (103) reported a similar prevalence of hypertension (47%) in their
17 pediatric PD patients aged over 6 years, and an even higher prevalence (70%) when
measured with ABPM. In contrast to us, they did not find a significant difference in BP
between their nephrectomized and non-nephrectomized patients. The higher prevalence of
high blood pressure in our nephrectomized patients, even though most of them were on
antihypertensive medication, as compared with that of Lingens et al., can be explained by
the lower age of our patients, which hampers determination of normal dry weight and
increases the risk of hypervolemia. The BP profile seems also to be altered in pediatric PD
patients. Both in our study and in a few previous studies, the mean nocturnal decline in BP
was less than in healthy children (103, 165).
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BP was measured with an automatic oscillometric Dinamap device. Dinamap has
been studied in neonates, infants, and young children, and has been shown to provide an
accurate BP determination as compared with direct arterial measurements (166, 167).
Lingens et al. used the European normal values for BP, obtained with a mercury column
manometer (168), both for casual BP measurements and for ABPM, because European
ABPM normal values (104) were not available in 1995.  However, we were not able to use
either the European normal values for casual BP (168) or for ABPM (104), as both are
available only for older children.
LVH may be due to uremia, hypertension, chronically elevated cardiac output induced by
anemia, or extracellular fluid volume overload (121). Sixty percent of our younger, mostly
nephrectomized patients had LVH, and 70% had interventricular septal hypertrophy. LVH
and the severity of hypertension were correlated significantly. Systolic and diastolic
function, however, were not impaired. Johnstone et al. reported less LVH and normal
diastolic function in their pediatric PD patients (125), and Morris et al. found more LVH
in addition to diastolic dysfunction (124). The cardiac impairment in the latter patients can
be partly attributed to anemia, and Morris et al. have subsequently shown reduction of the
left ventricular mass, and a trend toward improvement in diastolic ventricular function
following treatment with rHuEPO (127). All our prospectively studied patients received
rHuEPO and their mean hemoglobin was 110 g/L. Their BUN and creatinine were also
stable. Even so, 58% of our nephrectomized patients had LVH. The patients with
congenital nephrosis are not uremic before nephrectomy (5), and LVH did not correlate
with the mean time elapsed since nephrectomy. Thus, it is unlikely that LVH was present
before nephrectomy or was caused by uremia. In nephrectomized patients, renal
hypertension can be excluded. LVH was later reduced during dialysis with improved
blood volume control (decreased BP and ANP-N). Thus, the most important factor
causing hypertension and cardiac hypertrophy in our younger nephrectomized patients
seemed to be hypervolemia.
In adults, ANP-N has been shown to correlate with the decrement in relative blood
volume (116), and even better with LVH and LV dysfunction than ANP-C (117-119). In
children, ANP-N has been shown to be significantly higher in patients with congenital
heart disease than in healthy controls (120), but no data about ANP-N in pediatric PD
patients are available. As LVH usually is a consequence of chronic volume and/or
pressure overload, our observation of increased ANP-N levels correlating with BP and
LVM (%) may reflect changes in the regulation of ANP secretion through blood volume
changes during PD. ANP-N correlated better with BP than with LVM (%), and ANP-N
levels in our patients were higher (3.6 nmol/L) than in the cardiac patients of Holmström
et al. (1.06 nmol/L) (120). Together, these suggest even stronger stimulation of ANP
release in response to increased cardiac load through hypervolemia. This claim is
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supported by the decreased ANP-N and BP in three of our hypertensive patients after
fluid removal.
Pulmonary edema was more common before 1995. During the 80s, rHuEPO was
not used and the patients were more anemic, which would have influenced their cardiac
function. In addition, they received a mean of 12 erythrocyte transfusions annually,
increasing the risks for volume overload in a nephrectomized child. During recent years,
with rHuEPO and  intensified clinical care, complications such as pulmonary edema have
been avoided. Even so, however, 52% of our patients were hypertensive. Thus, our
findings confirm the difficulty of estimating the exact dry weight from the clinical status,
weight, and BP measurements. ANP-N seems to be a better tool than ANP-C for
facilitating the recognition of increased blood volume in PD patients. Another option for
identifying increased blood volume could be bioelectrical impedance analysis (BIA) (169-
173). However, the routine use of BIA measurements has been restricted by the expensive
equipment and lack of cross-validation of the published prediction equations.
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CONCLUSIONS
This study summarizes the peritoneal dialysis outcome in 34 children under 5 years of age
treated at the Hospital for Children and Adolescents, University of Helsinki, during 1986-
1994, and 30 children (15 of them under 5 years of age) followed prospectively during
intensified clinical care and a controlled dialysis dose after the introduction of regular
PETs and adequacy measurements in 1995-1999. The main conclusions of the study are:
1. PD outcome improved in the children under 5 years of age and did not differ
significantly in the children under and over 5 years of age during intensified clinical
care and PD adequacy control. However, peritonitis frequency in the children under 5
years of age remained higher than in the older children.
2. Peritoneal transport kinetics is age-independent. No significant difference was found in
the dialysate-to-plasma ratios for urea, creatinine, glucose, sodium, potassium,
phosphate, or albumin between the patients under and over 5 years of age, nor was any
correlation found with age. The mass transfer area coefficients were also age-
independent.
3. Catch-up growth occurred in most children in response to optimal nutrition, dialysis,
and clinical care. Growth further improved after the PD adequacy controls were started.
4. Tidal PD provides adequate dialysis for children under and over 5 years of age, but is a
more effective treatment modality than CCPD only in patients with high peritoneal
membrane permeability. Because of the higher cost, it should be reserved for patients
with high membrane permeability combined with reduced ultrafiltration, and for those
with mechanical outflow problems or outflow pain.
5. A clear diminution of complications related to high blood pressure was observed
during intensified clinical care and optimized peritoneal dialysis. However, the
prevalence of hypertension was higher in the patients under 5 years of age, which was
due to the difficulty of estimating the exact dry weight from clinical status, weight, and
BP measurements in a growing child.
6. The most important etiological factor causing hypertension in the prospectively studied
patients was hypervolemia. ANP-N is a better measure than ANP-C for the
recognition of increased blood volume during PD. ANP-N over 3.0 nmol/L with
hypertension was indicative of hypervolemia in pediatric PD patients.
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